Compare BHB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHB | ADCT |
|---|---|---|
| Founded | 1887 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.8M | 484.4M |
| IPO Year | 1995 | 2019 |
| Metric | BHB | ADCT |
|---|---|---|
| Price | $32.16 | $4.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $36.67 | $7.75 |
| AVG Volume (30 Days) | 167.4K | ★ 757.8K |
| Earning Date | 04-16-2026 | 03-10-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ 2.31 | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | $22.68 | N/A |
| Revenue Next Year | $3.66 | $68.29 |
| P/E Ratio | $13.93 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $26.43 | $1.05 |
| 52 Week High | $36.05 | $4.98 |
| Indicator | BHB | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 48.69 |
| Support Level | $28.38 | $3.79 |
| Resistance Level | $32.60 | $4.77 |
| Average True Range (ATR) | 0.96 | 0.26 |
| MACD | 0.12 | -0.05 |
| Stochastic Oscillator | 87.44 | 19.74 |
Bar Harbor Bankshares Inc is a bank holding company along with its subsidiaries that offers a full range of financial services products, brokerage services through third-party brokerage arrangements and also trust and investment management services to individuals, businesses, non-profit organizations, and municipalities. The company has following reportable segments such as Commercial construction, Commercial real estate owner occupied and non-owner occupied, Tax Exempt, Commercial and industrial loans, Residential real estate, Home equity and Consumer other. Its products and services consist of checking, deposits, cards, mobile banking, online services, loans, merchant services, trust, and fiduciary services, investment planning, education funding, individual retirement planning..
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).